Fig. 2From: Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinomaBone Pseudoprogression after anti-PD1 therapy seen in 18F-FDG PET/CT’s. Sagital fused images from different 18F-FDG PET/CT’s. a Multiple focal FDG uptake in different thoracic vertebrae (T1, T3 and T7) without tomographic focal lesion (arrows), corresponding to bone metastasis. b Same corresponding thoracic bone lesions with significant increased uptake (arrowsheads), consistent with metabolic progression disease. c Metabolic resolution of most thoracic bone lesions, consistent with partial metabolic response (PMR)Back to article page